Global Stem Cells Group (GSCG) and Dr. Yanti Aesthetic Clinic Elevate Regenerative Medicine Landscape with New Stem Cell Center in Jakarta
Miami, Florida – Global Stem Cells Group (GSCG) is thrilled to announce the grand opening of its latest state-of-the-art Stem Cell Center, located in Jakarta, Indonesia. This momentous occasion marks a significant stride forward in the field of regenerative medicine and showcases GSCG’s commitment to providing innovative healthcare solutions worldwide.
In a groundbreaking partnership with the esteemed Dr. Yanti Aesthetic Clinic, GSCG introduces its third Stem Cell Center in Indonesia, complementing existing facilities in Surabaya and Bandung. Further underscoring their dedication to advancing medical research, GSCG also anticipates the unveiling of a fourth location in Bali in the near future.
The launch of the Stem Cell Center in Jakarta serves as a beacon of innovation, the International Society for Stem Cell Application (ISSCA), GSCG’s educational division, conducted a groundbreaking training session alongside Dr. Alan Gaveck. This session spotlighted the transformational potential of NK cell therapies in treating Cancer and Anti-aging concerns, further cementing GSCG’s pioneering influence.
A distinctive feature of this collaboration is the authorization granted to Dr. Yanti Aesthetic Clinic to leverage GSCG’s brand, technologies, products, and treatment protocols. Operating as a franchise, the center proudly carries the brand, adhering to meticulous organizational guidelines, while being owned and operated by Dr. Yanti Aesthetic Clinic. This symbiotic arrangement seamlessly merges shared expertise with individual ownership, fostering a harmonious blend of vision and innovation.
Beyond its role as a clinical hub, the newly inaugurated Stem Cell Center will also serve as a focal point for ISSCA’s training initiatives in Asia. In addition to the pioneering NK cell therapy training conducted at the clinic, the center will facilitate educational programs to empower medical professionals across the continent with cutting-edge insights and advancements in regenerative medicine.
Benito Novas, an esteemed figure in the realm of regenerative medicine and the head of Public Relations for GSCG and ISSCA, shared his insights during the inaugural event, stating, “Global Stem Cells Group is dedicated to democratizing regenerative medicine access on a global scale. We encourage physicians to embrace the clinical and aesthetic applications of stem cell therapy, enabling patients around the world to experience the transformative benefits of regenerative treatments.”
Reflecting on the journey that led to this momentous occasion, Novas continued, “Dr. Yanti and I met in Brussels back in 2018, when this ambitious endeavor was but a vision. Today, as we witness the fruition of that vision, I express my profound gratitude for the privilege of collaborating with Dr. Yanti Aesthetic Clinic in ushering in the future of regenerative medicine.”
Dr. Yanti Kushmiran, Director of the DR. Yanti Aesthetic Clinic, echoed these sentiments, stating, “Our partnership with GSCG, a trailblazer with over a decade of pioneering work, resonates deeply with our commitment to excellence. The establishment of our third Stem Cell Center in Indonesia under the esteemed Global Stem Cells Group brand strengthens our ability to provide enhanced services to our patients, ushering in a new era of regenerative healthcare.”
With the inauguration of the Stem Cell Center in Jakarta, GSCG and Dr. Yanti Aesthetic Clinic take a significant stride towards advancing regenerative medicine’s frontiers. This landmark collaboration is poised to shape the future of medical care, leveraging cutting-edge technologies and expertise to benefit patients across the Asian continent and beyond.
About Dr. Yanti Aesthetic Clinic:
Dr. Yanti Aesthetic Clinic is a revered healthcare institution renowned for its state-of-the-art aesthetic and regenerative treatments. With an unwavering dedication to excellence and a forward-thinking approach, Dr. Yanti Aesthetic Clinic is poised to shape the future of regenerative medicine in Indonesia and beyond.
About the International Society for Stem Cell Application (ISSCA):
The International Society for Stem Cell Application (ISSCA) serves as the educational arm of Global Stem Cells Group (GSCG), dedicated to promoting knowledge and expertise in stem cell therapy and regenerative medicine. ISSCA empowers medical professionals across the globe with essential insights and advancements in the field.
About Global Stem Cell Group
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Releases
Global Stem Cells Group Announces New President of the International Society for Stem Cell Application (ISSCA)
Miami, Florida – Global Stem Cells Group, a leading organization in the field of regenerative medicine, is pleased to announce the appointment of Dr. Salih Yildirim as the new President of the International Society for Stem Cell Application (ISSCA), a division of Global Stem Cells Group. Dr. Yildirim previously held the position of Director of Overseas Operations at ISSCA.
Dr. Salih Yildirim brings a wealth of experience and expertise to his new role as President of ISSCA. Having previously served as the Director of Overseas Operations, Dr. Yildirim has demonstrated his exceptional leadership skills and strategic vision throughout his career. He has played a vital role in expanding ISSCA’s international presence and fostering collaborations with stakeholders worldwide.
In a statement regarding the appointment, Dr. Daeyong Kim, the former President of ISSCA, expressed his confidence in Dr. Yildirim’s ability to lead the organization. Dr. Kim stated, “I think you are the best leader and the most prepared to be the President of ISSCA. Therefore, I think you should be the head of ISSCA.” Dr. Kim will now transition to other support functions within ISSCA.
Benito Novas, head of Public Relations for ISSCA, expressed his admiration for Dr. Salih Yildirim’s professional qualities. Novas said, “I have known and worked with Dr. Salih for more than 10 years, and I am honored to have him as President within the company. During these years, he has proven to be an exceptional leader with a great vision for ISSCA.”
ISSCA’s objectives under the leadership of Dr. Salih Yildirim will include advancing the understanding and application of stem cell therapies, promoting scientific research and collaboration among professionals in the field, and advocating for the ethical and responsible use of regenerative medicine worldwide. Dr. Yildirim’s extensive experience in business development, international relations, and regenerative medicine will undoubtedly contribute to the achievement of these objectives.
About Dr. Salih Yildirim:
Dr. Salih Yildirim holds a bachelor’s and master’s degrees in business administration from Cleveland State University (United States) and a Ph.D. in health management from the University of Health Sciences. He has held various key positions throughout his career, including Director of Overseas Operations at ISSCA. Dr. Yildirim is currently the General Manager of BioTrend Medical International, a biotechnology firm specializing in genetics, molecular biology, and stem cell technologies. He also serves as the chief executive officer of ReGen.IC Clinic, specializing in regenerative medicine and stem cell applications. Additionally, he is a member of the International Society for Stem Cell Application’s Board of Directors and the Global Stem Cell Group’s Board of Directors and International Operations Manager. Dr. Yildirim is also a member of Istanbul Atlas University’s Board of Directors. He is married and a proud father.
About ISSCA
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and regenerative medicine.
ISSCA updates its members on advances in stem cell research, MSC, exosomes, and regenerative medicine
The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.
The international community provides a platform for practitioners to interact with scientists and build medical networks necessary for marketing.
As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities worldwide. The goal is to encourage more physicians to practice regenerative medicine and make it available to patients nationally and internationally. Incorporated under the Republic of Korea as a non-profit company, the ISSCA is focused on fostering excellence and standards in regenerative medicine.
About Global Stem Cells Group
Global Stem Cells Group is the parent company of six companies that are dedicated to stem cell research, solutions, and technology training. The group was founded in 2012 and combines dedicated researchers, patient educators, and physician trainers with the shared goal of meeting the need for high-end stem cell solutions and treatments.
Given that the group has a singular focus in this field, it is uniquely positioned to become the global leader in cellular medicine. In addition, by bringing together leading professionals in cellular medicine, it can discover issues that the industry faces and focus its research and development in this area. This specialization has, undoubtedly, enabled it to come up with solutions that address some of the significant issues that most stakeholders are facing in the industry.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Releases
ISSCA launched its first regenerative medicine training in Hormonal Modulation and Gynecology
Miami, Florida – The International Society for Stem Cell Application (ISSCA), a division of Global Stem Cells Group (GSCG), successfully launched its inaugural training course in Hormonal Modulation and Gynecology, marking a significant milestone in the field of regenerative medicine. The course, held from June 10-12, 2023, in Cancun, Mexico, generated immense enthusiasm among participants as the Global Stem Cell Group demonstrated its commitment to disseminating cutting-edge training and information to medical professionals worldwide.
Led by a Well-Respected Doctor
Under the guidance of Dr. Jorge Alberto Elias, a renowned Gynecologist and Urogynecologist with over a decade of experience in Cellular Therapies, participants had the privilege of learning from a highly respected expert in the field. His expertise ensured that attendees received valuable and up-to-date information, enhancing the quality of their educational experience.
The event was divided between two esteemed venues, with the theoretical portion taking place at the Four Points Hotel, and the hands-on training conducted at the prestigious Cellular Hope Institute.
ISSCA commitment to advancing regenerative medicine was further demonstrated by the inclusion of over 30 doctors who joined the event remotely, accessing the conferences and the live proceedings through online channels. This approach enabled medical professionals worldwide to be part of the educational experience, even if they couldn’t attend in person. By embracing technology, the company expanded the reach of knowledge dissemination and fostered a global community of practitioners dedicated to staying at the forefront of regenerative medicine.
The training program focused on equipping doctors and medical professionals with the latest advancements in regenerative medicine, with a specific emphasis on gynecology. Participants delved into the cutting-edge techniques and breakthrough procedures that are shaping the field.
Three Days of Intense Learning
The three-day program was divided into theoretical sessions and hands-on practical training. The theoretical portion took place at the Four Points Hotel, where participants delved into the intricacies of hormonal modulation and its application in gynecology. Dr. Silvina Pastrana, director of ISSCA education in Latam, complemented the program with a session on Exosomes, stem cells, and automatic closed processing techniques using the GCell machine, providing a comprehensive overview of the latest advancements.
During the practical segment, participants convened at the Cellular Hope Institute, where they were immersed in real-life scenarios and witnessed the application of regenerative measures in gynecological cases. Seven diverse cases were presented, including Labiaplasty, Perineum Vaginoplasty, Lichen Sclerosus, Liposuction Mount of Venus, and Lipo fat transfer with open and closed techniques. Through these hands-on demonstrations, attendees gained practical skills and insights into utilizing regenerative medicine to enhance patients’ quality of life.
Reflecting on the success of the event, Benito Novas, Head of Public Relations for the International Society for Stem Cell Application, expressed his enthusiasm, stating, “We are delighted to further expand the ISSCA faculty and specialty areas, opening the door for all physicians to utilize the latest Regenerative Medicine technologies in their area of expertise. Our goal is to provide the best education and training in regenerative medicine and cellular therapies so that professionals can offer the highest quality care to their patients.”
ISSCA celebrates the tremendous success of this inaugural regenerative medicine training course and remains committed to expanding access to the latest knowledge and advancements in the field. By empowering medical professionals globally, ISSCA aims to help patients worldwide benefit from the latest strategies and breakthroughs in regenerative medicine.
About ISSCA
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advances in science, technology, and regenerative medicine.
ISSCA updates its members on advances in stem cell research, MSC, exosomes, and regenerative medicine
The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.
The international community provides a platform for practitioners to interact with scientists and build medical networks necessary for marketing.
As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities worldwide. The goal is to encourage more physicians to practice regenerative medicine and make it available to patients nationally and internationally. Incorporated under the Republic of Korea as a non-profit company, the ISSCA is focused on fostering excellence and standards in regenerative medicine.
About Global Stem Cells Group
Global Stem Cells Group is the parent company of six companies that are dedicated to stem cell research, solutions, and technology training. The group was founded in 2012 and combines dedicated researchers, patient educators, and physician trainers with the shared goal of meeting the need for high-end stem cell solutions and treatments.
Given that the group has a singular focus in this field, it is uniquely positioned to become the global leader in cellular medicine. In addition, by bringing together leading professionals in cellular medicine, it can discover issues that the industry faces and focus its research and development in this area. This specialization has, undoubtedly, enabled it to come up with solutions that address some of the significant issues that most stakeholders are facing in the industry.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Releases
Global Stem Cells Group Announces Opening of New Research Facility at Marmara University’s Main Campus in Istanbul, Turkey
Collaboration Set to Propel Regenerative Medicine Research and Innovation
Miami, May 20, 2023 – Global Stem Cells Group, a leading provider of regenerative medicine solutions, is thrilled to announce the opening of its state-of-the-art research facility at Marmara University’s Main Campus in Istanbul, Turkey. This collaborative endeavor between Global Stem Cells Group, ReGen (described below), and Marmara University aims to advance research and knowledge in the fields of neurological conditions, autoimmune diseases, and the validation of safety and efficacy of procedures and Cellgenic products.
ReGen, a globally recognized network of clinics and a commercial partner of Global Stem Cells Group, is dedicated to providing cutting-edge cellular therapies that enhance patient well-being. This joint effort between ReGen, Global Stem Cells Group, and Marmara University seeks to drive research and innovation in cell therapy and tissue engineering.
Renowned for its commitment to excellence in education, research, and innovation, Marmara University provides an exceptional foundation for Global Stem Cells Group’s new research facility. With a strong emphasis on interdisciplinary collaboration and forefront research, Marmara University has emerged as a hub of intellectual discovery and academic achievement. The University’s renowned faculty and state-of-the-art infrastructure make it an ideal partner for Global Stem Cells Group in driving advancements in regenerative medicine.
By establishing this collaborative research facility at Marmara University, Global Stem Cells Group plans to access to the university’s wealth of expertise and resources, enabling the organization to undertake extensive clinical studies and groundbreaking research. Together, they will focus on addressing the challenges posed by neurodegenerative diseases and other medical conditions, aiming to develop innovative treatments and therapies that can significantly improve patient outcomes.
“Both Global Stem Cell Group and its commercial partner, ReGen, are thrilled to establish our new research facility in partnership with Marmara University.” Benito Novas, CEO of Global Stem Cells Group, expressed his enthusiasm for the collaboration. “This collaboration holds significant meaning for us, particularly in terms of the Cellgenic brand,” he added.
The Cellgenic product line encompasses a range of point-of-care regenerative medicine products, including autologous and allogeneic therapies, as well as exosomes. After examining the independent testing and validation of these products employed by Marmara University, Global Stem Cell Group is confident in the University’s quality and effectiveness.
The newly inaugurated research facility is expected to serve as a hub for extensive clinical studies on various medical conditions, with a particular focus on neurodegenerative diseases and ailments treatable through cell therapy and tissue engineering. This research is expected to contribute to the advancement of medical knowledge and the development of innovative treatments that have the potential to transform the lives of patients worldwide.
Global Stem Cells Group and its commercial partner, ReGen, extend their gratitude to Marmara University for its unwavering commitment to advancing regenerative medicine research and innovation. The collaboration between Global Stem Cells Group, ReGen, and Marmara University signifies what the parties believe is a significant milestone in the field of regenerative medicine, combining the expertise and resources of three leading institutions to drive breakthrough discoveries and shape the future of healthcare.
For more information about Global Stem Cells Group and its regenerative medicine solutions, please visit https://www.stemcellsgroup.com/.
About Global Stem Cells Group
Global Stem Cells Group is a leading provider of regenerative medicine solutions, dedicated to advancing healthcare through innovative therapies. With a global presence and a multidisciplinary team of experts, the organization strives to harness the potential of stem cells and regenerative medicine to improve patient outcomes across various medical fields. Through its extensive network of clinics, research facilities, and training centers, Global Stem Cells Group is committed to pushing the boundaries of regenerative medicine and making a positive impact on global healthcare.
About ReGen
ReGen is a renowned network of clinics and commercial partner of Global Stem Cells Group worldwide, offers cutting-edge cellular therapies to enhance the well-being of its patients. ReGen aims to drive research and innovation in cell therapy and tissue engineering together with Global Stem Cells Group and Marmara University.
About Marmara University
Marmara University is a prestigious educational institution renowned for its commitment to excellence in education, research, and innovation. With a strong emphasis on interdisciplinary collaboration and cutting-edge research, Marmara University has emerged as a hub of intellectual discovery and academic achievement. The university’s renowned faculty and state-of-the-art infrastructure make it an ideal partner for Global Stem Cells Group in driving advancements in regenerative medicine.
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Releases
ISSCA is Pleased to Announce the Launch of its Comprehensive Online Course in Regenerative and Functional Medicine for Obesity Management
The International Society for Stem Cell Application (ISSCA) is proud to announce the launch of its latest online course, “Curso en Medicina Funcional Regenerativa y Obesidad / Course in Functional Regenerative Medicine and Obesity.” This comprehensive course is designed to provide students with a deep understanding of various aspects of obesity treatment, metabolic syndrome, and post-procedure management of patients.
“This course should provide students with the knowledge and skills necessary to succeed in the field of regenerative and functional medicine,” said Benito Novas, Managing Director of Global Stem Cells Group and Head of Public Relations for the International Society for Stem Cell Application from the USA. “We are committed to providing students with a comprehensive understanding of the latest advancements in the field and how to effectively care for patients”.
The course covers various key concepts of regenerative and functional medicine for obesity management, and gastric balloon, a safe and effective non-surgical treatment, as one of them. The course will feature in-depth insights into the fundamentals of this procedure and how they can be used to help patients achieve and enjoy healthy weight loss. Additionally, post-procedure management approaches and protocols, will be covered.
Apart from balloon therapy, the course will also explore a wide range of other related topics, such as vitamins, exosomes, trace elements, minerals, hydrolyzed collagen, and more, and their significance in obesity management. These topics should prove useful to practitioners and course other course attendees in understanding metabolic syndrome and the best post-procedure practices for managing patients.
The course will be taught by two highly experienced and well respected professionals in the field of medicine:
Dr. Mario Ojeda, Director and Member of the Chilean Society of Aesthetic Medicine and Surgery (SOCHIMCE). An international reference and renowned expert in various areas, including obesity, intragastric balloons, endoscopic gastroplasty, stem cells, gastroenterology, digestive endoscopy, and colonoscopy, Dr. Mario Ojeda is “pleased to be part of this comprehensive online course and to provide students with the necessary knowledge and skills to advance the field of regenerative and functional medicine.”
Dr. Silvina Pastrana, Head of the ISSCA chapter in Latin America. She is a specialist in general surgery and has extensive experience in aesthetic and anti-aging medicine, orthomolecular medicine and nutrition, cellular therapies, and more. As a trainer in cellular therapies, she is well-equipped to provide students with a comprehensive understanding of the latest advancements in the field.
ISSCA is committed to advancing knowledge in regenerative and functional medicine for better obesity management. This comprehensive online course should provide physicians and specialists with a complete understanding of the latest advancements in the field and how to effectively manage patients, post-procedure.
For more information about the course and how to enroll, please visit the ISSCA visit the ISSCA website, send an email to info@stemcellsgroup.com, or call +1305 560 5337
About ISSCA
The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians who aspire to treat diseases and lessen human suffering through advancements in regenerative medicine. It is the educational division of the Global Stem Cells Group focused on promoting excellence and standards in the field of regenerative and functional medicine.
Through training and advancement courses, ISSCA aims to encourage physicians and specialists to practice new and advanced regenerative medicine approaches to benefit patients globally. It also ensures that practitioners learn, meet, and adhere to the necessary regenerative medicine standards and certifications.
About Global Stem Cells Group:
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
- Published in Press Releases
Mesenchymal Stem Cells For Cardiovascular Diseases
Despite progress in cardiovascular research, cardiac pathology continues to be one of the most common causes of morbidity and mortality in the world. Stem cell-based therapy has been recognized as an innovative strategy for the repair, regeneration and functional recovery of the myocardium, hence, once the animal research stage has been overcome, most clinical trials aimed at evaluating the safety and effectiveness of regenerative medicine in cardiovascular diseases have focused on angina pectoris, myocardial infarction and chronic cardiomyopathy. Although the current evidence of benefit is not conclusive, the evidence in favor of favorable results is growing.
In some cases, stem cell therapy can provide an effective treatment or alternative for diseases or disorders for which there is no effective treatment. Because these cells are capable of dividing into a wide range of lineages and tissues, they can be used to treat various diseases by repairing, replacing, and regenerating tissues.
It is unclear how umbilical cord mesenchymal stem cells act on the heart, but previous studies have shown that they possess an anti-apoptotic effect. The induced cardiomyocytes can form discs interspersed with myocytes from the host cells, creating a functional syncytium that will help contract the heart. Mesenchymal stem cells can improve cardiac function and reduce damage caused by cardiovascular disease, since they stimulate endogenous repair mechanisms, the regulation of the immune response, tissue perfusion and the proliferation of the resident heart rate, thereby improving cardiac function and reducing damage severity.
Refractory angina
This syndrome, characterized by persistent angina despite standard medical treatment, is often not revascularized due to diffuse coronary lesions or severe comorbidities.
In 2017, a review included 13 clinical studies, with 1061 patients and 12 months of follow-up on average, indicating cell therapy has emerged as a tool for managing these patients. Although the available data are inconclusive, the authors conclude that stem cell-based therapy could be a viable addition to conventional treatment options for refractory angina, given the paucity of therapeutic alternatives.
There was a reduction in mortality at two years after a meta-analysis in 2018, involving 304 patients, showed improved exercise tolerance and reduced angina attack frequency at three, six and 12 months. An additional meta-analysis published in March 2019, involving 526 patients monitored for 14 months, showed that patients treated with stem cells had fewer serious adverse effects, fewer deaths, fewer angina attacks, and fewer antianginal medications than those treated with conventional management.
A third meta-analysis from 2019, with 269 patients and 15 months of follow-up on average, reports the following results: decreased all-cause mortality, decreased frequency of angina and increased exercise time, with no increase in adverse reactions.
Cardiomyopathy (ischemic and non-ischemic)
Despite optimal medical and surgical management, many patients with heart failure undergo long-term myocardial remodeling that does not allow them to restore their ventricular function. This is because current treatment protocols cannot reverse the loss of cardiomyocytes due to cardiomyopathy. Since inflammatory responses continue over time as a central mechanism in the development of heart failure, it was of interest to investigate the anti-inflammatory, antifibrotic, and immunomodulatory properties of stem cells in patients with ischemic and non-ischemic cardiomyopathy.
In a review of five clinical studies published between 2017 and 2018, including 605 patients, the authors conclude that cell therapy is safe, causes immunomodulatory effects, improves functional capacity, and adds clinical benefits to standard therapies. According to them, the results are promising, and further evidence strengthening is recommended.
Based on a meta-analysis published in May 2019, involving 20 investigations and 1418 patients evaluated for an average of 21 months, stem cells improved cardiac function indicators (LVEF and LVESV), walking distance, functional classification of heart failure, quality of life, and mortality as compared to controls. Hospitalizations and serious adverse events were not different from those in the control group.
In a recent review of 9 studies involving 612 patients with heart failure, improvement was found in clinical and paraclinical parameters, evaluated on average for 9 months. According to the authors, stem cells are an effective therapy for the treatment of heart failure, improving patient prognosis and ability to exercise.
Acute myocardial infarction (AMI)
The application of stem cells was associated with a significant increase in left ventricular ejection fraction (LVEF) and other variables indicative of improved ventricular function and modification of remodeling in patients with AMI receiving timely percutaneous coronary intervention (PCI) and conventional medication in different studies. Even coronary artery bypass grafting with stem cells offers greater benefits. A number of studies have also shown that intravenous administration could be a more efficient and effective method of treating the heart or coronary arteries than direct application, with logistic, safety, and cost advantages.
Stem cell therapy is evidenced to be a safe way to treat cardiovascular diseases, as it shows an anti-apoptotic effect, reduction of lesion size, improvement of cardiac function through regulation of the immune response, adequate tissue perfusion and activation of growth factors.
We still need to explore a lot of ground, in terms of these and other conditions. You can learn more about regenerative medicine and stem cells by enrolling in our international certification program at www.issca.us
- Published in Corporate News / Blog
Atherosclerosis obliterans grade IV: Application of Autologous Stem Cells
Atherosclerosis is the most common form of arterial occlusive disease in adults. About 15 percent of adults over 55 years of age suffer from critical ischemia, the most severe form of this disease.
Due to the gradual aging of the population and the growing number of people in their third age group, a number of studies have been conducted in order to improve the prognosis of atherosclerosis obliterans and to find alternatives to the mutilation of the extremities. As a general rule, chronic ischemia of the lower limbs should be treated to alleviate symptoms, particularly pain, prevent disease progression, and reduce the rate of amputations. In most patients with critical ischemia, the main goal is to preserve the affected limb.
The development of regenerative medicine is closely linked to the development of new knowledge about embryonic and adult stem cells, as well as the regenerative and therapeutic potential of stem cell therapy. The use of adult stem cells in the treatment of peripheral artery diseases has been demonstrated as a therapeutic agent for inducing angiogenesis. Recent preclinical studies as well as the pioneering clinical studies indicate that bone marrow-derived mononuclear cells (MBMCs) can enhance tissue vascularization in ischemic limbs, with results similar to those obtained with peripheral blood stem cells supply.
Cuba presented the first studies carried out in 2004 at the Institute of Hematology of the “Enrique Cabrera” hospital in Havana City, which achieved encouraging clinical results and had very few adverse effects in recent years.
A progressive rise in the accumulated experience with stem cells was also observed in Pinar del Rio in 2005, as the first 10 cases were carried out. The rising ease of obtaining this type of cell has made research and applications with these cells advance rapidly with great expectations in terms of clinical application.
A study published by Dia-Diaz, et al. in the Journal of Medical Sciences of Pinar del Rio examined 296 patients with grade IV atherosclerosis obliterans between 2009 and 2019. During the study, autologous stem cells were injected intramuscularly from peripheral blood. Within four weeks, pain relief was observed, as well as an increase in the pain-free claudication distance. Angiography after treatment revealed collateral vessel formation. The limb was saved in 201 patients (68%), while 95 cases (32%) presented amputation criteria. Complications were not reported following the procedure.
The study demonstrated the effectiveness of the implantation of autologous stem cells obtained from peripheral blood, as well as the favorable evolution of patients, clinical improvement of rest pain, walking distance without claudication and ankle-brachial pressure index.
We still need to explore a lot of ground, in terms of these and other conditions. You can learn more about regenerative medicine and stem cells by enrolling in our international certification program at www.issca.us
- Published in Corporate News / Blog
The emerging role of MSC-derived exosomes in Regenerative Medicine
In recent years, MSCs have been introduced as respectable candidates for regenerative medicine due to their pro-angiogenic, anti-apoptotic, and immunomodulatory attributes. A variety of human tissues can be used as a source of mesenchymal stem/stromal cells (MSCs), ranging from bone marrow (BM) to umbilical cord (UC). These cells are typically multipotent and can differentiate into a variety of cell types. MSCs have been studied extensively for potential applications in cardiomyopathy, neurodegenerative disorders, spinal cord injuries (SCI), kidney injuries, liver injuries, lung injuries, and even cancer. According to current research, MSC-derived extracellular vesicles (EVs) contribute to MSC-exerted therapeutic benefits.
As defined by the International Society for Extracellular Vesicles (ISEV), EVs are lipid bilayer particles secreted by cells that do not replicate. EVs can be categorised into three subclasses based on size and biogenesis procedures: surrounding exosomes (50-150 nm), microvesicles (MVs) (100-1000 nm), and apoptotic bodies (ApoBDs) (500-5000 nm). In order for exosomes to be produced, multiple steps must occur; endosomes must be created from the plasma membrane, intraluminal vesicles must be formed within multivesicular bodies by inward budding, the MVB must merge with the plasma membrane, and finally the internal vesicles must be released.
By transmitting their molecules, such as proteins, messenger RNA (mRNA), and microRNAs (miRNAs), MSC exosomes stimulate phenotypic changes and subsequently modify regenerative programs of target organs. A number of mechanisms are involved in phenotypic alterations, including prevention of apoptosis, cell proliferation, immunomodulatory reactions, attenuation of oxidative stress, and improving oxygen supply to recipient cells. By supporting mitochondrial transfer, MSC-exosomes can suppress inflammatory cytokine production and induce phenotype 2 alveolar macrophages (M2), leading to acute lung injury (ALI) rescue. It has been demonstrated that the transmission of miRNAs from MSC-exosomes to recipient cells is responsible for the restoration of damaged kidneys, hearts, livers, and brains
Various cells continuously form and secrete exosomes, including lymphocytes, platelets, mast cells, intestinal epithelium, dendritic cells, neoplastic cell lines, microglia, neurons, and MSCs. Studies have shown that exosomes play an important role in cell-to-cell communication as well as several physiological and pathological processes. Despite their inherent biological activities, exosomes have recently been introduced as encouraging drug carriers because of their small size, high biocompatibility, and ability to hold different therapeutic ingredients, including proteins, nucleic acids, and small molecules. There have been reports showing the usefulness of MSCs-exosomes for treating a variety of ailments, such as lung, kidney, liver, neurodegenerative, cardiac, and musculoskeletal diseases, as well as skin wounds in vivo.
As well as their remarkable therapeutic effects, MSC-EVs derived from diverse sources also possess a variety of physiological functions that may affect their therapeutic application. In a wide range of human disorders, MSC-exosomes are considered an effective alternative to whole-cell therapy because of their low immunogenicity and improved safety profile. Although MSC-exosome applications still face various challenges, their benefits and capabilities are attracting increasing interest.
To learn more about exosomes and their clinical applications or if you’re interested in boosting your clinical practice with exosomes, go to our website www.cellgenic.com
- Published in Corporate News / Blog
Global Stem Cells Group announces the opening of a new Stem Cell Center in Bandung, Indonesia
Miami, FL, December 12, 2022 – Global Stem Cells Group (GSCG) is pleased to announce the opening of a new Stem Cell Center in Bandung, Indonesia in partnership with the Dr. Yanti Aesthetic Clinic. This joint venture will be the second in the country as they already have another facility in the stunning City of Surabaya.
The New Global Stem Cell Group Facility is Expected to Transform the Regenerative Medicine Field
The GSCG’s new center in Bandung aims to increase awareness about the benefits of regenerative medicine. Its launch strengthened the relationship between GSCG and the Dr. Yanti Aesthetic Clinic. This new facility is expected to transform regenerative medicine in the following ways:
- Offering accessible stem cell therapy to Indonesians;
- Promoting regenerative medicine technology; and
- Inspiring other doctors and industry experts to explore regenerative medicine.
Top Government Officials Attended the Launch of the Global Stem Cell Group Office in Bandung
The launch of the new Global Stem Cell Group facility in Bandung was a remarkable event in the medical field. The Minister of Tourism was among the top officials that witnessed the launch. Furthermore, the office of the Vice President sent several representatives.
What the President of Global Stem Cell Group Has to Say
Benito Novas, the president of the GSCG, was among the top industry specialists that graced the launch of the company’s second facility in Indonesia. According to him, GSCG wants to make regenerative medicine readily available for patients worldwide. Likewise, the company is encouraging more doctors to adopt stem cell therapy’s clinical and aesthetic applications in their work.
Benito Novas said: “We are dedicated to making it possible for both doctors and patients in all parts of the world to experience the benefits of regenerative medicines. The company is expanding and establishing itself as a market leader.”
The Director of the Dr. Yanti Aesthetic Clinic Appreciates GSCG
Dr. Yanti Kushmiran, director of the DR. Yanti Aesthetic Clinic, is once again honored to be part of this step into the future of regenerative medicine with its second Stem Cell Center in Indonesia together with the leading company Global Stem Cells Group.
Regarding this new clinic, Dr. Yanti says “We are honored to be part of GSCG, which has a more than 10-year track record in the market and a strong international reputation and to open a second cell therapy and regenerative medicine center facility under the Stem Cell Center brand. We will be able to provide more services to our patients as a result of this new partnership.”
Another GSCG Clinic is Opening in Indonesia by January 2023
The Global Stem Cell Group will continue increasing patients’ access to advanced regenerative medicine. As a result, the company plans to open another branch in Jakarta, the Capital of Indonesia. GSCG and its partners plan to launch this third facility in January 2023.
About Global Stem Cell Group
The Global Stem Cell Group is a family of several companies focused on stem cell medicine and research. The company uses its network to bring leadership in regenerative medicine training, research, and patient applications.
GSCG’s mission is to allow physicians to present the benefits of stem cell medicine to patients worldwide. The company also partners with policymakers, educators, and regulators to promote regenerative medicine.
Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/
To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331
- Published in Press Releases
New advances in osteoarthritis therapy with stem cells
Osteoarthritis is a rheumatic pathology that damages the articular cartilage. By joining two bones through the joint capsule, the joints are able to move, providing us with functional autonomy. An inner fluid called synovial fluid is usually found within joints, which is produced by the synovial membrane. Articular cartilage covers the ends of the bones that form the joint. As a result of damage to this articular cartilage, pain, stiffness, and functional impairment occur. Osteoarthritis is the most common joint disorder, usually beginning between the ages of 40 and 50, affecting to some degree almost everyone over the age of 80. Typically, osteoarthritis affects the spine, shoulders, fingers, hips, knees, and toe joints.
Stem cell therapies have the potential to treat a broad spectrum of diseases. Whether it’s rhizarthrosis, diabetes, neurodegenerative diseases, spinal cord injuries, or heart disease. By utilizing stem cells, regenerative medicine is capable of repairing tissues in affected areas. The main difference between lipo gem therapy and other treatments for osteoarthritis is that lipogem therapy regenerates cartilage, avoids surgery and its sequelae, and improves the quality of life for patients.
The potential for medical treatments with stem cells and their by-products is currently very high. In the field of sports medicine and traumatology, one of the most outstanding advances has been made for the first time in decades recently: Spanish scientists have achieved a degree of tendon regeneration in 100% of injured patients, resulting in a decrease in pain and a return to sport within two months, and just six months after the trial was completed.
A research performed by the Institute of Regenerative Tissue Therapy (ITRT), published by the prestigious American Journal of Sports Medicine. Demonstrates how this therapy regenerates chronic lesions in the patellar tendon and opens up a new therapeutic option for this tissue, which was considered impossible to regenerate.
In most patients, fat tissue can be harvested minimally invasively (under local or general anesthesia), providing a highly viable MSC population regardless of donor age. Similar to MSCs derived from other tissues, adipose tissue-derived MSCs have regenerative potential. As osteoarthritis is a very common joint disease, and knee osteoarthritis is the most common form, it is necessary to review scientific literature on osteoarthritis treatments with stem cells, like lipogems.
Lipogems Therapy
Lipogems therapy is a novel procedure that enhances the body’s natural ability to heal itself through the innovative power of science and biotechnology. The Lipogems method involves injecting mesenchymal stem cells into the joints. Adipose-derived mesenchymal stem cells have enormous regenerative potential. They also have a regenerative capacity independent of their age. Even older individuals can benefit from this procedure.
Injection of mesenchymal stem cells into the knee, particularly in the early stages of osteoarthritis, can stop the process of inflammation and degeneration, especially in the less advanced stages of the disease. In addition to preventing progressive physical deterioration of the articular cartilage, this treatment contributes significantly to a patient’s well-being and prevents the installation of knee prostheses.
Patellar tendinopathy, physiotherapeutic treatment and stem cell therapy
Injuries to the patellar tendon that connects the kneecap to the tibia are known as patellar tendinopathy or patellar tendinitis. The patellar tendon works with the muscles in the front of the thigh to extend the knee so you can kick, run and jump. Athletes who perform frequent jumping in their sports, such as basketball and volleyball, are most likely to suffer from patellar tendonitis. However, people who don’t engage in jumping sports may develop patellar tendonitis. Patients with patellar tendinitis usually begin treatment with physical therapy to stretch and strengthen their knee muscles.
Strength training with eccentric resistance is one of the most common treatments for tendinopathies. Alternatively, it has been demonstrated that bone marrow-derived mesenchymal stem cells (MSCs) can regenerate injured patellar tendons. Within six months of treatment, it has been observed that the structure of this tissue – which is always difficult to treat – is restored, reaching a regeneration of 40% in all injured persons, with a gradual improvement that eventually becomes complete.
It has been found that traditional management methods, including isometric or eccentric exercises, shock wave therapy, and even surgery, are not effective. As part of a rehabilitation program in chronic patellar tendinopathy, autologous expanded bone marrow mesenchymal stem cells (BM-MSC) or leukocyte-poor platelet-rich plasma (Lp-PRP) may be effective in reducing pain and improving activity levels. Traditional management, which includes isometric or eccentric exercises, shock wave therapy, and even surgery, has limited success. A combination of autologous expanded bone marrow mesenchymal stem cells (BM-MSCs) and leukocyte-poor platelet-rich plasma (Lp-PRP) and rehabilitation may reduce pain and improve activity levels in active participants with chronic patellar tendinopathy.
To learn more about stem cells, cellular therapies and keep up to date with all the information about regenerative medicine and its advances, sign up for our international certification in regenerative medicine at www.issca.us
- Published in Corporate News / Blog
